Major Depressive Disorder Clinical Trial
Official title:
Efficacy of Transdiagnostic Internet-based CBT for Early Illness Unipolar Depression and Anxiety
NCT number | NCT02266693 |
Other study ID # | 057/2012 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2014 |
Est. completion date | August 2018 |
Verified date | February 2019 |
Source | Centre for Addiction and Mental Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This 8-week, pilot randomized, controlled trial to evaluate the benefits of transdiagnostic Internet-based CBT (iCBT) in young adults with MDD, SAD, PD or GAD. The investigators hypothesize that patients who receive iCBT will show significant improvement in anxiety symptoms and functioning, compared to a wait-list group. This pilot randomized controlled study will assess the efficacy of transdiagnostic iCBT in 60 young adults.
Status | Completed |
Enrollment | 77 |
Est. completion date | August 2018 |
Est. primary completion date | August 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 29 Years |
Eligibility |
Inclusion Criteria: 1. Age range (18-29 years). 2. Primary diagnosis of MDD, SAD, PD and/or GAD, per the DSM-IV-TR. 3. A score =17 on the first 17 items of the Hamilton Depression Rating Scale (HAM-D)55 4. A score =17 on the Hamilton Anxiety Rating Scale (HAM-A)56. 5. Score =50 on the Leibowitiz Social Anxiety Scale (LSAS),57 =10 on the Panic Disorder Severity Scale (PDSS)58 and/or =60 the Penn State Worry Questionnaire (PSWQ).59 6. Currently unmedicated or on stable and adequate doses of medication for at least 4 weeks. 7. Co-morbidities are allowed and will be documented. Exclusion Criteria: 1. Primary diagnosis of any psychotic disorder or any other anxiety disorder (OCD, PTSD). |
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Addiction and Mental Health | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Centre for Addiction and Mental Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Hamilton Depression Rating Scale (HAM-D) Total Score | Baseline to study endpoint (Week 8) | ||
Primary | Change in Hamilton Anxiety Rating Scale (HAM-A) Total Score | Baseline to study endpoint (Week 8) | ||
Primary | Change in Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) Total Score | Baseline to study endpoint (Week 8) | ||
Primary | Change in Liebowitz Social Anxiety Scale (LSAS) Total Score | Baseline to study endpoint (Week 8) | ||
Primary | Change in Panic Disorder Severity Scale Total Score | Baseline to study endpoint (Week 8) | ||
Primary | Change in Penn State Worry Questionnaire Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Sheehan Disability Scale (SDS) Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Clinical Global Impression (CGI) | Baseline to study endpoint (Week 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |